<ul><li>Molecular diagnostics startup Tvaster Genkalp has raised $1.25 million in a pre-Series A funding round led by Ideaspring Capital.</li><li>The funding will be used to accelerate the expansion and commercialisation of Episcreen Liver, a liquid biopsy test for early liver cancer detection.</li><li>Tvaster Genkalp develops high-accuracy genetic solutions, focusing on non-invasive cancer detection and precision oncology.</li><li>Liver cancer cases are on the rise globally, and Tvaster aims to improve early detection and patient outcomes through their innovative diagnostic tests.</li></ul>

Molecular diagnostics startup Tvaster Genkalp raises $1.25 million in a pre-Series A round

Discover more